MCID: PTT009
MIFTS: 55

Pituitary Gland Disease

Categories: Endocrine diseases, Neuronal diseases

Aliases & Classifications for Pituitary Gland Disease

MalaCards integrated aliases for Pituitary Gland Disease:

Name: Pituitary Gland Disease 12 15
Pituitary Dysfunction 55 73
Pituitary Diseases 55 73
Pituitary Disorders 43
Pituitary Disease 12

Classifications:



External Ids:

Disease Ontology 12 DOID:53
ICD9CM 35 253.1
ICD10 33 E23.6

Summaries for Pituitary Gland Disease

MedlinePlus : 43 Your pituitary gland is a pea-sized gland at the base of your brain. The pituitary is the "master control gland" - it makes hormones that affect growth and the functions of other glands in the body. With pituitary disorders, you often have too much or too little of one of your hormones. Injuries can cause pituitary disorders, but the most common cause is a pituitary tumor.

MalaCards based summary : Pituitary Gland Disease, also known as pituitary dysfunction, is related to hypopituitarism and hypoadrenalism, and has symptoms including seizures, tremor and back pain. An important gene associated with Pituitary Gland Disease is PRL (Prolactin), and among its related pathways/superpathways are Peptide ligand-binding receptors and Cushing syndrome. The drugs Dexmedetomidine and Hydrocortisone acetate have been mentioned in the context of this disorder. Affiliated tissues include pituitary, brain and hypothalamus, and related phenotypes are endocrine/exocrine gland and growth/size/body region

Disease Ontology : 12 An endocrine system disease that is located in the pituitary gland.

Wikipedia : 76 In vertebrate anatomy, the pituitary gland, or hypophysis, is an endocrine gland about the size of a pea... more...

Related Diseases for Pituitary Gland Disease

Diseases related to Pituitary Gland Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 225)
# Related Disease Score Top Affiliating Genes
1 hypopituitarism 30.2 CRH GH1 GHRH GNRH1 HESX1 IGF1
2 hypoadrenalism 29.9 CRH GH1 POMC
3 galactorrhea 29.9 IGF1 PRL
4 growth hormone deficiency 29.8 GH1 GHRH HESX1 IGF1
5 fibromyalgia 29.7 CRH IGF1 PRL
6 acth-secreting pituitary adenoma 29.6 CRH POMC PRL
7 multiple endocrine neoplasia, type i 29.6 GHRH INS MEN1 PRL SST
8 mccune-albright syndrome 29.6 GH1 IGF1 PRL SST
9 polycystic ovary syndrome 29.6 GNRH1 IGF1 INS PRL
10 ovarian disease 29.5 GNRH1 IGF1 INS PRL
11 inappropriate adh syndrome 29.5 AVP POMC
12 secondary adrenal insufficiency 29.5 AVP IGF1 INS
13 anorexia nervosa 29.5 CRH GH1 GHRH IGF1 POMC PRL
14 adenohypophysitis 29.4 GH1 POMC PRL TRH
15 conn's syndrome 29.3 CRH GH1 MEN1 POMC PRL SST
16 gigantism 29.3 AIP GH1 GHRH PRL
17 diabetes insipidus 29.2 AVP CRH INS POMC PRL
18 amenorrhea 29.1 CRH GNRH1 POMC PRL TRH
19 empty sella syndrome 29.0 GH1 GNRH1 IGF1 POMC PRL TRH
20 hyperprolactinemia 28.9 GH1 GNRH1 IGF1 POMC PRL SST
21 craniopharyngioma 28.7 GH1 GNRH1 IGF1 INS POU1F1 PRL
22 hypothyroidism 28.7 GH1 HESX1 IGF1 LHX3 POMC POU1F1
23 hypothyroidism, congenital, nongoitrous, 4 28.6 CRH GH1 IGF1 POMC POU1F1 PRL
24 pituitary tumors 28.5 AIP GH1 IGF1 MEN1 POMC POU1F1
25 acromegaly 28.1 AIP GH1 GHRH IGF1 INS MEN1
26 microphthalmia, syndromic 5 11.8
27 pallister-hall syndrome 11.7
28 optic nerve hypoplasia, bilateral 11.3
29 laurence-moon syndrome 11.0
30 hypothyroidism, central, and testicular enlargement 11.0
31 culler-jones syndrome 11.0
32 froelich syndrome 10.8
33 brain injury 10.4
34 traumatic brain injury 10.4
35 fibrous dysplasia/mccune-albright syndrome 10.3 GH1 PRL
36 bronchus adenoma 10.3 POMC SST
37 bronchial adenomas/carcinoids childhood 10.3 POMC SST
38 lymphocytic hypophysitis 10.3 GH1 POMC
39 non-functioning pituitary adenoma 10.3 GH1 SST
40 scleredema adultorum 10.3 INS POMC
41 pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities 10.3 IGF1 INS
42 prolactin producing pituitary tumor 10.2 PRL SST
43 neonatal thyrotoxicosis 10.2 LHX3 PROP1
44 duodenal somatostatinoma 10.2 INS SST
45 acidophil adenoma 10.2 IGF1 POMC SST
46 pancreatic somatostatinoma 10.2 MEN1 SST
47 postgastrectomy syndrome 10.2 INS SST
48 postural hypotension 10.2 INS SST
49 hypogonadotropism 10.2 GNRH1 PRL
50 gangliocytoma 10.2 CRH POMC

Graphical network of the top 20 diseases related to Pituitary Gland Disease:



Diseases related to Pituitary Gland Disease

Symptoms & Phenotypes for Pituitary Gland Disease

UMLS symptoms related to Pituitary Gland Disease:


seizures, tremor, back pain, pain, headache, syncope, chronic pain, sciatica, vertigo/dizziness, sleeplessness

MGI Mouse Phenotypes related to Pituitary Gland Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.28 AIP CRH GHRH GNRH1 HESX1 IGF1
2 growth/size/body region MP:0005378 10.25 AIP CRH GHRH GNRH1 HESX1 IGF1
3 homeostasis/metabolism MP:0005376 10.24 AIP AVP CRH GHRH GNRH1 IGF1
4 immune system MP:0005387 10.02 CRH GHRH GNRH1 IGF1 INS MEN1
5 liver/biliary system MP:0005370 9.86 AIP CRH GHRH GNRH1 INS MEN1
6 nervous system MP:0003631 9.83 AVP CRH GHRH GNRH1 HESX1 IGF1
7 neoplasm MP:0002006 9.63 AIP GNRH1 IGF1 MEN1 POMC PRL
8 reproductive system MP:0005389 9.28 GHRH GNRH1 IGF1 INS LHX3 MEN1

Drugs & Therapeutics for Pituitary Gland Disease

Drugs for Pituitary Gland Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 616)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 113775-47-6 68602 5311068
2
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-03-3
3
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-23-7 5754
4
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53-03-2 5865
5
Anastrozole Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 120511-73-1 2187
6
mometasone furoate Approved, Vet_approved Phase 4,Phase 3 83919-23-7
7
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492
8
Metyrapone Approved, Investigational Phase 4,Phase 3 54-36-4 4174
9
Mecasermin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 68562-41-4
10
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83150-76-9 383414 6400441
11
Pasireotide Approved Phase 4,Phase 2,Phase 3,Phase 1 396091-73-9 9941444
12
Somatostatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 51110-01-1, 38916-34-6 53481605
13 lanreotide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 108736-35-2
14
Aripiprazole Approved, Investigational Phase 4,Not Applicable 129722-12-9 60795
15
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-61-6, 62-31-7 681
16
Risperidone Approved, Investigational Phase 4,Phase 3,Not Applicable 106266-06-2 5073
17
Triamcinolone Approved, Vet_approved Phase 4,Not Applicable 124-94-7 31307
18
Racepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 329-65-7 838
19
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-43-4 5816
20
Methyltestosterone Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 58-18-4 6010
21
Testosterone undecanoate Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 5949-44-0
22
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-22-0 6013
23
Testosterone enanthate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 315-37-7 9416
24
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 57-83-0 5994
25
Zinc Approved, Investigational Phase 4,Phase 3,Not Applicable,Early Phase 1 7440-66-6
26
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1 657-24-9 14219 4091
27
Cabergoline Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 81409-90-7 54746
28
Tolvaptan Approved Phase 4,Phase 3,Phase 1,Phase 2 150683-30-0 216237
29
Ganirelix Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 123246-29-7, 124904-93-4 25081094
30
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1177-87-3
31
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
32
Leuprolide Approved, Investigational Phase 4,Not Applicable 53714-56-0 657181 3911
33 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 979-32-8
34
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-28-2 5757
35
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 28014-46-2
36
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
37
Acetaminophen Approved Phase 4 103-90-2 1983
38
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
39
Ibuprofen Approved Phase 4 15687-27-1 3672
40
Morphine Approved, Investigational Phase 4 57-27-2 5288826
41
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 302-25-0
42
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
43
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
44
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1 2921-57-5
45
Histamine Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 51-45-6, 75614-87-8 774
46
Loratadine Approved, Investigational Phase 4 79794-75-5 3957
47
Fluticasone Approved, Experimental Phase 4,Phase 3,Phase 1 90566-53-3 62924
48
Iodine Approved, Investigational Phase 4,Phase 2 7553-56-2 807
49
Sodium oxybate Approved Phase 4 502-85-2 5360545
50
Menotropins Approved Phase 4,Phase 2,Not Applicable 61489-71-2, 9002-68-0 5360545

Interventional clinical trials:

(show top 50) (show all 1094)
# Name Status NCT ID Phase Drugs
1 Effect of Dexmedetomidine on Plasmatic Cortisol Response in Transsphenoidal Surgery Unknown status NCT02549768 Phase 4 Dexmedetomidine;Sodium Chloride 0.9%
2 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
3 Phase IV Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children Unknown status NCT02314676 Phase 4
4 Aromatase Inhibitors and Weight Loss in Severely Obese Hypogonadal Male Veterans (Pilot) Unknown status NCT02959853 Phase 4 Anastrazole
5 Comparison of Efficacy and Safety of 0.1% Tacrolimus and 0.1% Mometasone Furoate for Adult Vitiligo Unknown status NCT01333410 Phase 4 tacrolimus ointment;Mometasone furoate
6 Cortisol and Nutritional Sympathetic Responsiveness Unknown status NCT01620684 Phase 4 metyrapone;placebo
7 Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT) Unknown status NCT00915954 Phase 4
8 Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone Deficiency Unknown status NCT02976675 Phase 4
9 Clinical Study of Pegylated Somatropin to Treat Children Growth Hormone Deficiency Unknown status NCT02908958 Phase 4
10 Pasireotide LAR and Pegvisomant Study in Acromegaly Unknown status NCT02668172 Phase 4 Pasireotide LAR 60 mg;Pegvisomant
11 Mindfulness-Based Cognitive Therapy for Depression and Anxiety Unknown status NCT02777905 Phase 4
12 A Multicenter Study to Evaluate the Effects of Switching to Aripiprazole 12 Weeks on the Sexual Dysfunction From Risperidone or Paliperidone in Patients With Schizophrenia Spectrum Disorders or Bipolar Spectrum Disorders Unknown status NCT01742390 Phase 4 Aripiprazole;risperidone or paliperidone
13 Effects of Sandostatin LAR® in Acromegaly Unknown status NCT01424241 Phase 4 Sandostatin LAR
14 Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant Unknown status NCT00552851 Phase 4 pegvisomant
15 Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia Unknown status NCT00541554 Phase 4 Abilify (aripiprazole)
16 Surgical Debulking of Pituitary Adenomas Completed NCT01371643 Phase 4 Octreotide LAR
17 Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors Completed NCT02351700 Phase 4 IV Caldolor (IV Ibuprofen);IV Ibuprofen placebo
18 Evaluation of Efficacy and Hypothalamus-pituitary-adrenal Axis Suppression Due to Corticosteroids Intrabursal Injection Completed NCT01652495 Phase 4 methylprednisolone acetate;Triamcinolone Acetonide
19 Nasacort AQ Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Children With Allergic Rhinitis Completed NCT01154153 Phase 4 Placebo nasal spray;Triamcinolone acetonide aqueous (TAA-AQ) nasal spray (NASACORT AQ);Placebo nasal spray;Claritin® Syrup
20 Anterior Pituitary Hormone Replacement in Traumatic Brain Injury Completed NCT00957671 Phase 4 Recombinant human growth hormone
21 Predictive Markers in Chinese Growth Hormone Deficiency (GHD) Children Treated With Saizen® Completed NCT01187550 Phase 4 Recombinant human growth hormone (r-hGH)
22 Preoperative Octreotide Treatment of Acromegaly Completed NCT00521300 Phase 4 Octreotide
23 Testosterone Gel Applied to Women With Pituitary Gland Problems Completed NCT00144391 Phase 4 Transdermal Testosterone gel
24 Study to Evaluate Effect of Pandel Cream 0.1% on HPA Axis in Pediatric and Adult Population Completed NCT01137032 Phase 4 Pandel Cream 0.1%
25 Cutivate Lotion HPA Axis Pediatric Study Completed NCT00546000 Phase 4 Fluticasone propionate 0.05% lotion
26 Octreotide Efficacy and Safety in First-line Acromegalic Patients Completed NCT00171886 Phase 4 Octreotide
27 Severe LH Suppressed Patients After Administration of a GnRH Antagonist Completed NCT01936077 Phase 4 Recombinant LH (Luveris)
28 Study of Radioiodine (131-I) Uptake Following Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal. Completed NCT00001730 Phase 4 Thyrogen
29 Exploratory Clinical Study to Evaluate Sodium Oxybate (Xyrem) on Potential Endocrine Changes Completed NCT00345800 Phase 4 Sodium Oxybate (Xyrem)
30 Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patients Completed NCT00642720 Phase 4 Pegvisomant
31 Study of Triamcinolone Acetonide on the Growth Velocity of Children, Ages 3 to 9, With Perennial Allergic Rhinitis (PAR) Completed NCT00449072 Phase 4 TAA-AQ, Nasacort® AQ;Claritin®
32 Effect of DPP4 Inhibition on Growth Hormone Secretion Completed NCT01701973 Phase 4 Sitagliptin;Pegvisomant;Placebo;L-NMMA;Exendin 9-39
33 Effects of Korean Red Ginseng on Semen Parameters in Male Infertility Patients: a Randomized, Placebo-controlled, Double-blind Clinical Study Completed NCT02204826 Phase 4 Korean Red Ginseng (KRG)
34 Viapaed Study In Children And Adolescents With Asthma Completed NCT00315744 Phase 4 Salmeterol/fluticasone;Fluticasone propionate;Salbutamol
35 Progesterone Serum Levels in Subfertile Female Patients Undergoing in Vitro Fertilisation (IVF) Completed NCT01225835 Phase 4 Menotrophin;Follitrophin alpha;Cetrorelix;Choriongonadotropin;Progesterone
36 Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment Completed NCT03080181 Phase 4 Pasireotide 0.6 MG/ML
37 Safety and Efficacy of SR-hGH (Sustained-release Human Growth Hormone, Declage Inj.) Completed NCT01605331 Phase 4 sustained-release recombinant human GH (SR-rhGH)
38 Effect of Somatropin on Left Ventricular Mass in Growth Hormone Deficient Adult Patients Completed NCT01562834 Phase 4 somatropin;placebo
39 Easypod United States User Trial Completed NCT00689260 Phase 4
40 Ultrasound Guided Octreotide LAR Injection in Acromegaly Completed NCT00552071 Phase 4 Octreotide LAR 30 MG Injection
41 A Post-Marketing Study of the Immunogenicity of Somatropin (Ribosomal Deoxyribo Nucleic Acid [rDNA] Origin) Injection (Nutropin AQ®) in Children With Growth Hormone Deficiency Completed NCT02311894 Phase 4 Somatropin
42 An Open-label Phase 4 Study to Explore Immunogenicity of the Liquid Formulation of Saizen® in Subjects With Adult Growth Hormone Deficiency (AGHD) Completed NCT01806298 Phase 4 Saizen® solution for injection (referred as Saizen®)
43 Comparison of Two Growth Hormone Dosing Methods in Adults With Growth Hormone Deficiency Completed NCT00490191 Phase 4 Somatropin
44 Growth Hormone and Endothelial Function in Children Completed NCT00373386 Phase 4 growth hormone
45 Comparison of a Needle-free Injection Method With a Needle-syringe Injection Method Completed NCT00990340 Phase 4
46 Growth Hormone and Glucose Metabolism Completed NCT00929799 Phase 4 recombinant human Growth Hormone (Genotropin® )
47 Liquid Somatropin Formulation in Children With Growth Hormone Deficiency Completed NCT00567385 Phase 4 somatropin
48 IGF1 Generation Test Completed NCT00145457 Phase 4
49 Investigating the Accuracy of the Home Glucose Monitors in Hypoglycemia Completed NCT01013402 Phase 4 Human insulin;Human Insulin
50 Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly Completed NCT00461149 Phase 4 Octreotide-LAR

Search NIH Clinical Center for Pituitary Gland Disease

Genetic Tests for Pituitary Gland Disease

Anatomical Context for Pituitary Gland Disease

MalaCards organs/tissues related to Pituitary Gland Disease:

41
Pituitary, Brain, Hypothalamus, Bone, Liver, Thyroid, Ovary

The Foundational Model of Anatomy Ontology organs/tissues related to Pituitary Gland Disease:

19
The Pituitary Gl

Publications for Pituitary Gland Disease

Articles related to Pituitary Gland Disease:

(show top 50) (show all 168)
# Title Authors Year
1
Patterns of pituitary dysfunction three months or more after traumatic brain injury. ( 30319953 )
2018
2
Posterior pituitary dysfunction following traumatic brain injury: review. ( 30334138 )
2018
3
Sports-Related Repetitive Traumatic Brain Injury: A Novel Cause of Pituitary Dysfunction. ( 30156462 )
2018
4
Hypothalamic and pituitary dysfunction is common in tubercular meningitis: A prospective study from a tertiary care center in Northern India. ( 30321796 )
2018
5
Secondary adrenal insufficiency and pituitary dysfunction in oral/transdermal opioid users with non-cancer pain. ( 30324794 )
2018
6
Pituitary Dysfunction in Pediatric Patients with Optic Nerve Hypoplasia: A Retrospective Cohort Study (1975-2014). ( 29176324 )
2018
7
Reflex and reflective testing strategies for early detection of pituitary dysfunction. ( 29486187 )
2018
8
Pituitary Dysfunction from an Unruptured Ophthalmic Internal Carotid Artery Aneurysm with Improved 2-year Follow-up Results: A Case Report. ( 29675480 )
2018
9
Pituitary dysfunction and association with fatigue in stroke and other acute brain injury. ( 29748174 )
2018
10
Pituitary dysfunction in survivors of Russell's viper snake bite envenomation: A prospective study. ( 30233002 )
2018
11
Sellar plasmacytoma presenting with symptoms of anterior pituitary dysfunction. ( 29204279 )
2017
12
Pituitary dysfunction in granulomatosis with polyangiitis. ( 28540625 )
2017
13
Assessment of the role of intracranial hypertension and stress on hippocampal cell apoptosis and hypothalamic-pituitary dysfunction after TBI. ( 28630478 )
2017
14
RETRACTION Novel perspectives on hypothalamic-pituitary dysfunction as a risk factor for non-alcoholic fatty liver disease. ( 27405476 )
2017
15
Pituitary dysfunction after traumatic brain injury: are there definitive data in children? ( 27872046 )
2017
16
Pituitary dysfunction in traumatic brain injury: Is evaluation in the acute phase worthwhile? ( 28217503 )
2017
17
The screening and management of pituitary dysfunction following traumatic brain injury in adults: British Neurotrauma Group guidance. ( 28860331 )
2017
18
Giant cavernous carotid aneurysm causing pituitary dysfunction: Pituitary function recovery with high-flow bypass. ( 28868192 )
2017
19
Plasminogen Activator Inhibitor Type 1: A Possible Novel Biomarker of Late Pituitary Dysfunction after Mild Traumatic Brain Injury. ( 28931364 )
2017
20
IGF-I levels reflect hypopituitarism severity in adults with pituitary dysfunction. ( 27083162 )
2016
21
Pituitary dysfunction following cranial radiotherapy for adult-onset nonpituitary brain tumours. ( 26501843 )
2016
22
Incidence of pituitary dysfunction following traumatic brain injury: A prospective study from a regional neurosurgical centre. ( 26610235 )
2016
23
Pituitary Dysfunction After Aneurysmal Subarachnoid Hemorrhage: A Systematic Review and Meta-analysis. ( 26645970 )
2016
24
Pituitary dysfunction and its association with quality of life in traumatic brain injury. ( 26708846 )
2016
25
Reduced Quality of Life in Patients with Pituitary Dysfunction After Aneurysmal Subarachnoid Hemorrhage: A Prospective Longitudinal Study. ( 26724609 )
2016
26
Clinical prevalence and outcome impact of pituitary dysfunction after aneurysmal subarachnoid hemorrhage: a systematic review with meta-analysis. ( 27287036 )
2016
27
Pituitary Dysfunction: A Case Series of Immune Checkpoint Inhibitor-Related Hypophysitis in an Emergency Department. ( 27451306 )
2016
28
Pituitary dysfunction after aneurysmal subarachnoid hemorrhage in Japanese patients. ( 27492047 )
2016
29
Systemic sarcoidosis with hypercalcaemia, hypothalamic-pituitary dysfunction and thyroid involvement. ( 27495178 )
2016
30
Can early clinical parameters predict post-traumatic pituitary dysfunction in severe traumatic brain injury? ( 27778105 )
2016
31
Prevalence of hypothalamo pituitary dysfunction in patients of traumatic brain injury. ( 27867878 )
2016
32
Symptoms of gonadal dysfunction are more predictive of hypopituitarism than nonspecific symptoms in screening for pituitary dysfunction following moderate or severe traumatic brain injury. ( 26252757 )
2015
33
Hypothalamic pituitary dysfunction amongst nasopharyngeal cancer survivors. ( 25134488 )
2015
34
Pituitary dysfunction after aneurysmal subarachnoid haemorrhage: course and clinical predictors—the HIPS study. ( 25378238 )
2015
35
High prevalence of pituitary dysfunction after aneurysmal subarachnoid hemorrhage: a long-term prospective study using dynamic endocrine testing. ( 25514615 )
2015
36
Pituitary Dysfunction After Aneurysmal Subarachnoid Hemorrhage. ( 25681597 )
2015
37
Early identification of pituitary dysfunction in congenital nasal pyriform aperture stenosis: recommendations based on experience in a single centre. ( 25791686 )
2015
38
Pituitary dysfunction after traumatic brain injury: a clinical and pathophysiological approach. ( 25950715 )
2015
39
Neutrophil function in healthy aged horses and horses with pituitary dysfunction. ( 25962580 )
2015
40
PITUITARY DYSFUNCTION IN DEVELOPMENTAL DELAY: MEDICAL AND ETHICAL CONCERNS. ( 26121462 )
2015
41
Pituitary dysfunction following traumatic brain injury: clinical perspectives. ( 26251600 )
2015
42
Hypothalamus-pituitary dysfunction is common in patients with stable cirrhosis and abnormal low dose synacthen test. ( 26364559 )
2015
43
Pituitary dysfunction in granulomatosis with polyangiitis: the Mayo Clinic experience. ( 25077899 )
2014
44
Pituitary dysfunction after aneurysmal subarachnoid hemorrhage is associated with impaired early outcome. ( 24140998 )
2014
45
Prevalence of pituitary dysfunction after severe traumatic brain injury in children and adolescents: a large prospective study. ( 24635130 )
2014
46
Pituitary dysfunction in adult patients after cranial irradiation for head and nasopharyngeal tumours. ( 25236713 )
2014
47
Clinical characteristics and effects of GH replacement therapy in adults with childhood-onset craniopharyngioma compared with those in adults with other causes of childhood-onset hypothalamic-pituitary dysfunction. ( 23904277 )
2013
48
Post-traumatic head injury pituitary dysfunction. ( 22779906 )
2013
49
Hypothalamic-pituitary dysfunction following traumatic brain injury affects functional improvement during acute inpatient rehabilitation. ( 22613945 )
2013
50
Role of pituitary dysfunction on cardiovascular risk in primary empty sella patients. ( 23215853 )
2013

Variations for Pituitary Gland Disease

Expression for Pituitary Gland Disease

Search GEO for disease gene expression data for Pituitary Gland Disease.

Pathways for Pituitary Gland Disease

Pathways related to Pituitary Gland Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.54 AVP CRH GH1 GHRH GNRH1 POMC
2
Show member pathways
12.08 AIP CRH MEN1 POMC
3
Show member pathways
11.94 GH1 GHRH GNRH1 IGF1
4 11.75 GH1 IGF1 INS
5
Show member pathways
11.72 GH1 IGF1 INS POMC
6 11.42 AVP CRH GHRH POMC
7 11.41 POMC POU1F1 PRL
8 11.4 GH1 GHRH GNRH1 IGF1
9 10.1 CRH POMC

GO Terms for Pituitary Gland Disease

Cellular components related to Pituitary Gland Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.65 AVP CRH GH1 GHRH GNRH1 IGF1
2 secretory granule GO:0030141 9.56 AVP POMC PRL TRH
3 perikaryon GO:0043204 9.5 CRH GHRH GNRH1
4 extracellular region GO:0005576 9.36 AVP CRH GH1 GHRH GNRH1 IGF1
5 endosome lumen GO:0031904 9.33 GH1 INS PRL

Biological processes related to Pituitary Gland Disease according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.99 AVP GNRH1 IGF1 LHX3 PROP1
2 positive regulation of cell proliferation GO:0008284 9.87 AVP CRH GHRH IGF1 INS POU1F1
3 cellular protein metabolic process GO:0044267 9.85 IGF1 INS MEN1 PRL
4 female pregnancy GO:0007565 9.77 CRH GNRH1 PRL
5 response to organic cyclic compound GO:0014070 9.76 AVP GNRH1 PRL TRH
6 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.73 GH1 IGF1 INS
7 positive regulation of multicellular organism growth GO:0040018 9.67 GH1 GHRH POU1F1
8 positive regulation of glycolytic process GO:0045821 9.63 IGF1 INS
9 response to corticosterone GO:0051412 9.62 CRH TRH
10 negative regulation of release of cytochrome c from mitochondria GO:0090201 9.61 AVP IGF1
11 positive regulation of glycogen biosynthetic process GO:0045725 9.61 IGF1 INS
12 pituitary gland development GO:0021983 9.61 HESX1 LHX3 POU1F1
13 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.58 GH1 PRL
14 parturition GO:0007567 9.58 CRH PRL
15 ovulation cycle GO:0042698 9.57 GNRH1 PRL
16 response to ethanol GO:0045471 9.55 AVP CRH GNRH1 PRL TRH
17 negative regulation of feeding behavior GO:2000252 9.54 INS TRH
18 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.54 GH1 GHRH IGF1
19 hormone-mediated apoptotic signaling pathway GO:0008628 9.52 CRH SST
20 somatotropin secreting cell differentiation GO:0060126 9.51 POU1F1 PROP1
21 cell-cell signaling GO:0007267 9.5 AVP GHRH GNRH1 INS POMC SST
22 positive regulation of lactation GO:1903489 9.48 GHRH PRL
23 adenohypophysis development GO:0021984 9.43 GHRH POU1F1 PROP1
24 regulation of signaling receptor activity GO:0010469 9.32 AVP GH1 GHRH GNRH1 IGF1 INS
25 positive regulation of transcription by RNA polymerase II GO:0045944 10.09 IGF1 LHX3 MEN1 POMC POU1F1 PROP1
26 G protein-coupled receptor signaling pathway GO:0007186 10.01 AVP CRH GHRH GNRH1 INS POMC

Molecular functions related to Pituitary Gland Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.36 AVP CRH GH1 GHRH GNRH1 IGF1
2 neuropeptide hormone activity GO:0005184 9.33 AVP CRH GHRH
3 insulin-like growth factor receptor binding GO:0005159 9.26 IGF1 INS
4 prolactin receptor binding GO:0005148 8.96 GH1 PRL

Sources for Pituitary Gland Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....